Literature DB >> 10623824

Modulation of renal disease in MRL/lpr mice genetically deficient in the alternative complement pathway factor B.

H Watanabe1, G Garnier, A Circolo, R A Wetsel, P Ruiz, V M Holers, S A Boackle, H R Colten, G S Gilkeson.   

Abstract

In systemic lupus erythematosus, the renal deposition of complement-containing immune complexes initiates an inflammatory cascade resulting in glomerulonephritis. Activation of the classical complement pathway with deposition of C3 is pathogenic in lupus nephritis. Although the alternative complement pathway is activated in lupus nephritis, its role in disease pathogenesis is unknown. To determine the role of the alternative pathway in lupus nephritis, complement factor B-deficient mice were backcrossed to MRL/lpr mice. MRL/lpr mice develop a spontaneous lupus-like disease characterized by immune complex glomerulonephritis. We derived complement factor B wild-type (B+/+), homozygous knockout (B-/-), and heterozygous (B+/-) MRL/lpr mice. Compared with B+/- or B+/+ mice, MRL/lpr B-/- mice developed significantly less proteinuria, less glomerular IgG deposition, and decreased renal scores as well as lower IgG3 cryoglobulin production and vasculitis. Serum C3 levels were normal in the B-/- mice compared with significantly decreased levels in the other two groups. These results suggest that: 1) factor B plays an important role in the pathogenesis of glomerulonephritis and vasculitis in MRL/lpr mice; and 2) activation of the alternative pathway, either by the amplification loop or by IgA immune complexes, has a prominent effect on serum C3 levels in this lupus model.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10623824     DOI: 10.4049/jimmunol.164.2.786

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  64 in total

1.  The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation.

Authors:  M Harboe; G Ulvund; L Vien; M Fung; T E Mollnes
Journal:  Clin Exp Immunol       Date:  2004-12       Impact factor: 4.330

2.  Pivotal advance: The pattern recognition receptor ligands lipopolysaccharide and polyinosine-polycytidylic acid stimulate factor B synthesis by the macrophage through distinct but overlapping mechanisms.

Authors:  David J Kaczorowski; Amin Afrazi; Melanie J Scott; Joon H Kwak; Roop Gill; Rebecca D Edmonds; Yujian Liu; Jie Fan; Timothy R Billiar
Journal:  J Leukoc Biol       Date:  2010-04-22       Impact factor: 4.962

3.  Lupus Nephritis: Animal Modeling of a Complex Disease Syndrome Pathology.

Authors:  Tracy L McGaha; Michael P Madaio
Journal:  Drug Discov Today Dis Models       Date:  2014

Review 4.  Leukocytes in glomerular injury.

Authors:  Stephen R Holdsworth; Peter G Tipping
Journal:  Semin Immunopathol       Date:  2007-10-16       Impact factor: 9.623

5.  Distinct roles for the complement regulators factor H and Crry in protection of the kidney from injury.

Authors:  Jennifer Laskowski; Brandon Renner; Moglie Le Quintrec; Sarah Panzer; Jonathan P Hannan; Danica Ljubanovic; Marieta M Ruseva; Dorin-Bogdan Borza; Alexandra H Antonioli; Matthew C Pickering; V Michael Holers; Joshua M Thurman
Journal:  Kidney Int       Date:  2016-05-07       Impact factor: 10.612

6.  Activation-induced deaminase-deficient MRL/lpr mice secrete high levels of protective antibodies against lupus nephritis.

Authors:  Chuancang Jiang; Ming-Lang Zhao; Richard M Scearce; Marilyn Diaz
Journal:  Arthritis Rheum       Date:  2011-04

7.  The complement inhibitors Crry and factor H are critical for preventing autologous complement activation on renal tubular epithelial cells.

Authors:  Brandon Renner; Kathrin Coleman; Ryan Goldberg; Claudia Amura; Amanda Holland-Neidermyer; Kathryn Pierce; Heather N Orth; Hector Molina; Viviana P Ferreira; Claudio Cortes; Michael K Pangburn; V Michael Holers; Joshua M Thurman
Journal:  J Immunol       Date:  2010-07-30       Impact factor: 5.422

Review 8.  Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review.

Authors:  Maria Izabel de Holanda; Luis Cristóvão Pôrto; Teresa Wagner; Luis Fernando Christiani; Lilian M P Palma
Journal:  Clin Rheumatol       Date:  2017-09-13       Impact factor: 2.980

Review 9.  Complement and autoimmunity.

Authors:  Eleonora Ballanti; Carlo Perricone; Elisabetta Greco; Marta Ballanti; Gioia Di Muzio; Maria Sole Chimenti; Roberto Perricone
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

10.  Novel targets for immunotherapy in glomerulonephritis.

Authors:  Mary H Foster
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.